WebDoctor Encyclopedia

Central nervous system

Pineal parenchymal tumour of intermediate differentiation (PPTID)

PPTID is an uncommon tumour of the pineal gland that sits between the slow pineocytoma and the aggressive pineoblastoma. Most people need surgery, and some also need radiotherapy. Many do well, but long-term scans are important because it can return.

Medically reviewed Last reviewed October 20, 2026

What is a pineal parenchymal tumour of intermediate differentiation?

A pineal parenchymal tumour of intermediate differentiation (PPTID) is a rare brain tumour that starts in the cells of the pineal gland. This small gland lies near the centre of the brain and produces melatonin, the hormone that helps control the sleep-wake cycle. Its cells are called pinealocytes, and tumours that grow from them are called pineal parenchymal tumours.

The name “intermediate differentiation” describes how the tumour behaves. Its cells are more abnormal than those of a pineocytoma, a slow-growing grade 1 tumour, but less aggressive than those of a pineoblastoma, a fast-growing grade 4 tumour usually seen in children. PPTIDs are graded as WHO CNS grade 2 or 3, depending on how active the cells are under the microscope.

PPTID makes up less than 1% of all tumours that begin in the brain and spinal cord (Takase et al., 2022). It mostly affects adults, often in their 30s and 40s, but children and older people can also be affected. Most cause symptoms by blocking the flow of fluid around the brain, which leads to headaches and vomiting.

Laboratory research has shown that many PPTIDs carry small changes in a gene called KBTBD4. This finding helps pathologists tell PPTID apart from pineoblastoma (Lee et al., 2019).

Treatment usually starts with surgery to remove as much tumour as safely possible. Radiotherapy is often added, and chemotherapy may be used for higher-grade tumours. Because there are no large trials, treatment plans are tailored to each person by a specialist team.

1. Key facts at a glance

Feature Details
Type of tumour Pineal parenchymal tumour, WHO CNS grade 2 or 3
Where it grows Pineal gland, in the centre of the brain
How common Less than 1% of primary brain and spinal tumours
Typical age Adults; median age 36 in one series (range 13-73)
Main symptoms Headache, nausea, vomiting, eye-movement problems
Genetic hallmark Small in-frame insertions in the KBTBD4 gene
Spread Can spread through the brain fluid, sometimes years later
Main treatments Surgery, radiotherapy, chemotherapy for some
Outlook Variable; better after complete removal and for grade 2 tumours

2. Types

The pineal parenchymal tumour family

Tumour WHO grade Usual age Behaviour
Pineocytoma 1 Adults Slow-growing; often cured by surgery
PPTID 2 or 3 Adults Intermediate; may recur or spread
Pineoblastoma 4 Mostly children Aggressive; intensive treatment needed

Grade 2 versus grade 3 PPTID

Feature Grade 2 Grade 3
Cell division (mitoses) Few More frequent
Proliferation index (Ki-67) Lower Higher
Neurofilament staining Often present Often reduced
Risk of recurrence Lower Higher
Typical treatment Surgery, sometimes followed by focal radiotherapy Surgery, radiotherapy and often chemotherapy

A systematic review of 389 patients found that grading under the WHO classification was closely linked with survival (Takase et al., 2022). However, some tumours behave more aggressively than their grade suggests, which is why molecular tests are becoming more important.

Other tumours of the pineal region

Tumour Notes
Papillary tumour of the pineal region Arises from nearby specialised cells; often recurs locally
Germ cell tumours (germinoma and others) Mostly in teenagers and young adults; tumour markers may be raised
Pineal cyst Common, usually harmless fluid-filled sac
Glioma, meningioma, metastasis Less common in this location

3. Causes and risk factors

The cause of PPTID is not known.

Factor Notes
KBTBD4 gene changes Arise in the tumour cells; not inherited
Age Mainly adults
Sex Affects men and women
Lifestyle No known link
Inherited syndromes Rarely reported; pineoblastoma, not PPTID, is the tumour linked with DICER1 syndrome

PPTIDs typically lack the DROSHA deletions and DICER1 mutations found in many pineoblastomas (Lee et al., 2019). An international consensus study confirmed that PPTIDs form a distinct molecular group among pineal tumours (Liu et al., 2021).

4. How does it look

On scans

Feature Typical finding
Location Pineal region, behind the third ventricle
Size Often 2-4 cm at diagnosis
Appearance on MRI Solid mass, sometimes with cystic parts
Contrast enhancement Usually present, often uneven
Hydrocephalus Enlarged fluid spaces from blockage of the aqueduct
Spread Nodules along the brain or spinal lining in some cases

Under the microscope

Feature Description
Cell arrangement Sheets or lobules of cells
Cells Round nuclei with mild to moderate atypia
Rosettes Large pineocytomatous rosettes are usually absent
Staining Synaptophysin positive; neurofilament variable
Ki-67 index Helps distinguish grade 2 from grade 3
Molecular test KBTBD4 insertion or methylation profile consistent with PPTID

5. Symptoms

Symptoms are caused mainly by raised pressure in the head and by pressure on the midbrain.

Common symptoms

  • Headache, the most common symptom in one series, often worse in the morning (Webb et al., 2022)
  • Nausea and vomiting
  • Blurred or double vision
  • Difficulty looking upwards (Parinaud syndrome)
  • Unsteadiness when walking

Less common symptoms

Symptom Possible cause
Drowsiness or confusion Severe hydrocephalus
Memory problems Raised pressure
Hormone changes or sleep disturbance Rare effects on the pineal gland or nearby structures
Back pain, leg weakness or numbness Spread to the spine
Hearing problems Pressure on nearby pathways (rare)

When to seek urgent help

Get urgent medical help for a severe or worsening headache with vomiting, sudden visual change, drowsiness or confusion. These may signal dangerous pressure in the head.

6. Diagnosis

Test Purpose
MRI of the brain with contrast Shows the tumour and hydrocephalus
MRI of the whole spine Looks for spread along the spinal cord
Blood and fluid tumour markers (AFP, beta-hCG) Exclude germ cell tumours
Cerebrospinal fluid cytology Looks for tumour cells in the fluid
Biopsy or surgical removal Confirms the diagnosis and grade
Molecular testing KBTBD4 analysis or DNA methylation profiling
Eye examination Checks eye movements and swelling at the back of the eye

Managing hydrocephalus

Procedure What it involves
Endoscopic third ventriculostomy (ETV) A small opening in the floor of the third ventricle lets fluid bypass the blockage; a biopsy can be taken at the same time
Ventriculoperitoneal shunt A tube drains fluid to the abdomen
External drain A temporary drain in emergencies

Staging

PPTID is not staged like body cancers. Doctors record:

  • The grade (2 or 3)
  • Whether the tumour was fully removed
  • Whether there is spread in the brain fluid or spine

7. Treatment

An international consensus from neuro-oncology societies notes that treatment of pineal tumours ranges from surgery alone to intensive combined therapy, depending on the tumour type and its features (Liu et al., 2024).

Surgery

Aspect Details
Aim Remove as much tumour as safely possible
Approaches From above and behind the brain (supracerebellar infratentorial) or between the brain halves (occipital transtentorial)
Gross total resection Linked with better outcomes in pooled data (Webb et al., 2022)
Risks Eye-movement problems, bleeding, stroke, infection

Radiotherapy

Option When used
Focal radiotherapy to the tumour bed After incomplete removal or for grade 3 tumours
Craniospinal irradiation When the tumour has spread through the brain fluid
Stereotactic radiosurgery Small residual or recurrent tumours

The best type of radiotherapy remains uncertain. Whether radiotherapy to the whole brain and spine offers advantages over focal treatment is not clear (Webb et al., 2022).

Chemotherapy

Situation Notes
Grade 3 or aggressive PPTID Often combined with surgery and radiotherapy
Spread through the brain fluid Platinum-based regimens are commonly used
Recurrence Chosen case by case

For grade 3 and unusually aggressive tumours, a combination of maximal resection, radiotherapy and chemotherapy has been suggested as first-line treatment (Takase et al., 2022).

Treatment by situation

Situation Typical approach
Grade 2, fully removed, no spread Surgery, then close MRI follow-up; radiotherapy discussed
Grade 2, partly removed Focal radiotherapy
Grade 3, no spread Surgery, focal or craniospinal radiotherapy, sometimes chemotherapy
Any grade with spread Craniospinal radiotherapy with chemotherapy

Recovery after pineal surgery

Period What to expect
First days Close monitoring, often in a high-dependency unit
First 1-2 weeks Headache and tiredness; double vision may be worse at first
4-6 weeks Results of tumour analysis and a plan for further treatment
2-3 months Eye movement and balance often improve
Longer term Gradual return to work or study, sometimes on reduced hours

PPTID in children and older adults

PPTID is uncommon in children, and specialist paediatric teams plan treatment carefully to limit long-term effects of radiotherapy on growth, learning and hormones. In older adults, the team weighs the benefits of extensive surgery and radiotherapy against general health and other illnesses.

Side effects

Treatment Possible side effects
Pineal region surgery Double vision, difficulty looking up, balance problems, usually improving over weeks or months
Radiotherapy Tiredness, hair loss, memory and concentration changes, hormone problems
Craniospinal radiotherapy Low blood counts, nausea, longer-term effects on hormones and thinking
Chemotherapy Low blood counts, infection, nausea, hearing loss with cisplatin

8. Outlook (prognosis)

Factor Effect on outlook
Grade 2 Better outlook than grade 3
Complete removal Associated with fewer recurrences
Spread at diagnosis Poorer outlook
High proliferation index Higher risk of recurrence

In a pooled analysis of 36 patients from three centres, 16 experienced recurrence and median overall survival was 44 months (Webb et al., 2022). In the Mayo Clinic group within that analysis, no deaths were reported during follow-up.

Recurrence and spread through the spinal fluid can occur many years after treatment, so long-term follow-up is important.

9. Follow-up

Time Typical checks
First 2 years Brain MRI every 3-6 months; spine MRI as advised
Years 3-5 MRI every 6-12 months
After 5 years Yearly MRI, often for many years
Ongoing Eye, hormone and memory assessments as needed

10. Living with PPTID

  • Tell your team about new headaches, vision changes or back pain
  • Use eye exercises or prisms if you have double vision; orthoptists can help
  • Avoid driving until your doctor confirms it is safe and the licensing authority allows it
  • Pace yourself; tiredness after treatment is common and can last months
  • Ask for neuropsychology support if memory or concentration is affected
  • Seek support from brain tumour charities and support groups

11. Frequently asked questions

Question Answer
Is PPTID cancer? It is a malignant brain tumour of intermediate grade
How is it different from pineocytoma? It is more active and more likely to recur or spread
Is it the same as pineoblastoma? No; pineoblastoma is higher grade and genetically different
Will I need a shunt? Possibly, if fluid blockage persists; an ETV may avoid one
Will I need radiotherapy? Often, especially for grade 3 or incomplete removal
Is it inherited? No; the gene changes are in the tumour only
Can it come back? Yes, sometimes years later, so long-term scans are needed
Will my sleep be affected? Some people notice changes; melatonin and sleep advice can help
Can I work after treatment? Many people return, often with a phased plan

12. Questions to ask your care team

  • Is my tumour grade 2 or grade 3?
  • Has molecular testing confirmed the diagnosis?
  • Was the tumour completely removed?
  • Has it spread to the spine or brain fluid?
  • Do you recommend radiotherapy or chemotherapy?
  • What side effects should I expect?
  • How often will I need scans, and for how long?
  • Is there a specialist nurse I can contact between appointments?
  • Could I take part in a clinical trial?

Resources

  1. Lee, J.C. et al. (2019) ‘Recurrent KBTBD4 small in-frame insertions and absence of DROSHA deletion or DICER1 mutation differentiate pineal parenchymal tumor of intermediate differentiation (PPTID) from pineoblastoma’, Acta Neuropathologica, 137(5), pp. 851-854.
  2. Liu, A.P.Y. et al. (2021) ‘Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study’, Acta Neuropathologica, 141(5), pp. 771-785.
  3. Liu, A.P.Y. et al. (2024) ‘SNO-EANO-EURACAN consensus on management of pineal parenchymal tumors’, Neuro-Oncology, 26(12), pp. 2159-2173.
  4. Takase, H. et al. (2022) ‘Pineal parenchymal tumor of intermediate differentiation: a systematic review and contemporary management of 389 cases reported during the last two decades’, Neurosurgical Review, 45(2), pp. 1135-1155.
  5. Webb, M. et al. (2022) ‘Clinical experience and outcomes in patients with pineal parenchymal tumor of intermediate differentiation (PPTID): a single-institution analysis’, Journal of Neuro-Oncology, 160(2), pp. 527-534.
  6. National Cancer Institute (2026) Adult Central Nervous System Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.